The question of the immune response of the population, particularly of professional populations in contact with vulnerable populations (such as those with chronic conditions such as cancer), is an important issue. Knowing the evolution of this response over time in this population can help answer outstanding questions. The PRO-SERO-COV study is a seroprevalence study of caregivers working in the hospital sector with a follow-up at 3 months and 12 months. The objective is to evaluate and monitor at 3 and 12 months the serological immune status to an infection by the SARS-CoV-2 virus in active volunteer professionals working at the Institut Bergonié with different types of exposure: healthcare professionals and professionals in other services.
Other: PRO-SERO-COV
At inclusion, 3 months and 12 months :
blood sample (2 x 5ml)
self-administered questionnaire
Inclusion Criteria:
1. Adult 18 years-old and older.
2. Person in employment (on fixed-term or permanent contracts) since (at least) March
17th, 2020, the date of national implementation of containment measures in response to
the COVID-19 pandemic.
3. Signed informed consent.
4. Person affiliated to a French social security regimen in accordance with Article
1121-11 of the French Public Health Code).
Exclusion Criteria:
1. Report of known active SARS-CoV-2 infection within 10 days prior to the date of
signing the consent. Known active SARS-CoV-2 infection is defined as a positive result
on a diagnostic RT-PCR test.
2. Presence of known symptoms suggestive of COVID-19 within 10 days prior to the date of
signing consent: fever, fatigue, dry cough, shortness of breath, loss of taste and/or
smell, headache, body aches, aches and pains, conjunctivitis or colds, digestive
disorders (vomiting, diarrhea).
3. A person who is unable to follow and comply with research procedures due to
geographical, social or psychological reasons.
4. Pregnant or breastfeeding woman.
5. Person deprived of their liberty, incapable or incapable of giving their consent.
Institut Bergonié
Bordeaux, France
Simone MATHOULIN-PELISSIER, MD, PhD, Study Chair
s.mathoulin@bordeaux.unicancer.fr